Target family: VIP and PACAP receptors (type: gpcr)
Target: PAC<sub>1</sub> receptor

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6.7 pEC50
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.4 pKi
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6.3 pKi
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6.4 pEC50
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.8 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6 pEC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6 pKi
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.7 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6.4 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.7 pEC50
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.1 pEC50
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.5 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.1 pEC50
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.8 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: [125I]VIP (human, mouse, rat) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -

Ligand: [125I]PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.1 pKd
Reference (Journal): Essential structural motif in the C-terminus of the PACAP type I receptor for signal transduction and internalization.
Published in: Ann N Y Acad Sci

Ligand: [125I][Ac-His1]PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.300000190734863 pKd
Reference (Journal): Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist.
Published in: Eur J Biochem

Ligand: secretin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.5 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: Ro 25-1553 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6 pEC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: Ro 25-1553 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: Ro 25-1553 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5 pIC50
Reference (Journal): The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
Published in: Peptides

Ligand: PG 99-465 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.1 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PG 97-269 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 4.5 pIC50
Reference (Journal): In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Published in: Peptides

Ligand: PG 97-269 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: PACAP-(6-38) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.5 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-(6-38) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-(6-38) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.5 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-(6-38) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.1 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.5 pEC50
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.3 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9 pKi
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.8 pKi
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.2 pEC50
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.2 pEC50
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6.9 pKi
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 10.3 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.5 pEC50
Reference (Journal): Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist.
Published in: J Biol Chem

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.8 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 10 pEC50
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.4 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 10 pEC50
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.8 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 10 pEC50
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 10.1 pEC50
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.1 pEC50
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6.9 pKi
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pKi
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9 pEC50
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pKi
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.7 pEC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.6 pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.4 pEC50
Reference (Journal): N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants.
Published in: J Neuroendocrinol

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 10.6 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: N-stearyl-[Nle17] neurotensin-(6-11)/VIP-(7-28) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.2 pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: MK-0893 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.039999961853027 pIC50
Reference (Journal): Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.
Published in: J Med Chem

Ligand: maxadilan (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 10.300000190734863 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: maxadilan (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.199999809265137 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: M65 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.8 pIC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: M65 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.6 pIC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: [Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6 pEC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: [Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: [Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -

Ligand: BAY 55-9837 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5 pIC50
Reference (Journal): A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
Published in: Diabetes

Ligand: [Arg16]chicken secretin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -

Ligand: [Arg16]chicken secretin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.7 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: [Ala11,22,28]VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.8 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: [Ala11,22,28]VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: [Ac-His1]PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.3 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol

Ligand: [Ac-His1]PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8 pKi
Reference (Journal): Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells.
Published in: Eur J Pharmacol